Levodopa
|
|
Levodopa 속성
- 녹는점
- 276-278 °C (lit.)
- 끓는 점
- 334.28°C (rough estimate)
- 알파
- -11.7 º (c=5.3, 1N HCl)
- 밀도
- 1.3075 (rough estimate)
- 굴절률
- -12 ° (C=5, 1mol/L HCl)
- 저장 조건
- 2-8°C
- 용해도
- 물에는 약간 용해되고 에탄올에는 거의 용해되지 않습니다(96%). 1M 염산에는 잘 녹고 0.1M 염산에는 거의 녹지 않습니다.
- 산도 계수 (pKa)
- 2.32(at 25℃)
- 물리적 상태
- 결정성 분말
- 색상
- 흰색에서 크림색
- 냄새
- 100.00%에서. 냄새 없는
- ?? ??
- 냄새 없는
- optical activity
- -39.5 (H2O) -12.025 (1 mol dm-3 HCl)
- 수용성
- 물에 약간 용해되고 묽은 염산과 포름산. 에탄올에 불용성.
- Merck
- 14,5464
- BRN
- 2215169
- 안정성
- 안정적인. 강한 산화제와 호환되지 않습니다. 빛과 공기에 민감합니다.
- InChIKey
- WTDRDQBEARUVNC-LURJTMIESA-N
- LogP
- -1.154 (est)
- CAS 데이터베이스
- 59-92-7(CAS DataBase Reference)
- NIST
- Levodopa(59-92-7)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
위험품 표기 | Xn | ||
---|---|---|---|
위험 카페고리 넘버 | 22-36/37/38-20/21/22 | ||
안전지침서 | 26-36-24/25 | ||
WGK 독일 | 3 | ||
RTECS 번호 | AY5600000 | ||
F 고인화성물질 | 10-23 | ||
TSCA | Yes | ||
HS 번호 | 29225090 | ||
유해 물질 데이터 | 59-92-7(Hazardous Substances Data) | ||
독성 | LD50 in mice (mg/kg): 3650 ±327 orally, 1140 ±66 i.p., 450 ±42 i.v., >400 s.c.; in male, female rats (mg/kg): >3000, >3000 orally; 624, 663 i.p.; >1500, >1500 s.c. (Clark) | ||
기존화학 물질 | KE-10853 |
Levodopa C화학적 특성, 용도, 생산
개요
Levodopa is an amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS.화학적 성질
L-Dopa [59-92-7], levodopa, crystallizes as colorless, odorless, and tasteless needles from water, mp 276-278℃(decomp.). It is freely soluble in dilute hydrochloric and formic acids but practically insoluble in ethanol, benzene, chloroform, and ethyl acetate. Solubility in water is 66 mg/40 mL. In the presence of moisture, l-dopa is rapidly oxidized by atmospheric oxygen, with darkening.용도
Levodopa is an immediate precursor of dopamine and product of tyrosine hydroxylase. It derived from vanillin is widely used for treatment of Parkinson’s disease, most often in combination with peripheral decarboxylase inhibitors such as benserazide and carbidopa.정의
ChEBI: Levodopa is an optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease.Biological Functions
Levodopa (L-DOPA), the most reliable and effective drug used in the treatment of parkinsonism, can be considered a form of replacement therapy. Levodopa is the biochemical precursor of dopamine. It is used to elevate dopamine levels in the neostriatum of parkinsonian patients. Dopamine itself does not cross the blood-brain barrier and therefore has no CNS effects. However, levodopa, as an amino acid, is transported into the brain by amino acid transport systems, where it is converted to dopamine by the enzyme L-aromatic amino acid decarboxylase.If levodopa is administered alone, it is extensively metabolized by L-aromatic amino acid decarboxylase in the liver, kidney, and gastrointestinal tract. To prevent this peripheral metabolism, levodopa is coadministered with carbidopa (Sinemet), a peripheral decarboxylase inhibitor. The combination of levodopa with carbidopa lowers the necessary dose of levodopa and reduces peripheral side effects associated with its administration.
일반 설명
Levodopa belongs to a group of the most effective drugs for treating the type of Parkinsonism not caused by medicinal agents. The first significant breakthrough in the treatment of PDcame about with the introduction of high-dose levodopa. Fahn referred to this as a revolutionary development intreating parkinsonian patients. The rationale for the use oflevodopa for the treatment of PD was established in theearly 1960s. Parkinsonian patients were shown to have decreasedstriatal levels of DA and reduced urinary excretionof DA. Since then, levodopa has shown to be remarkablyeffective for treating the symptoms of PD.부작용
Get medical help immediately if you have any symptoms: fever, unusual muscle stiffness, severe confusion, sweating, fast/irregular heartbeat, and rapid breathing. A severe allergic reaction to this drug is rare. This medication may cause saliva, urine, or sweat to turn dark. This effect is harmless.Safety Profile
Poison by ingestion. Moderately toxic by intravenous and intraperitoneal routes. Human systemic effects by ingestion: somnolence, hallucinations and distorted perceptions, toxic psychosis, motor activity changes, ataxia, dyspnea. Experimental teratogenic and reproductive effects. Questionable human carcinogen producing skin tumors. Human mutation data reported. An anticholinergic agent used as an anti Parhnsonian drug. When heated to decomposition it emits toxic fumes of NOxPurification Methods
Likely impurities are vanillin, hippuric acid, 3-methoxytyrosine and 3-aminotyrosine. DOPA recrystallises from large volumes of H2O forming colourless white needles; its solubility in H2O is 0.165%, but it is insoluble in EtOH, *C6H6, CHCl3, and EtOAc. Also crystallise it by dissolving it in dilute HCl and adding dilute ammonia to give pH 5, under N2. Alternatively, crystallise it from dilute aqueous EtOH. It is rapidly oxidised in air when moist, and darkens, particularly in alkaline solution. Dry it in vacuo at 70o in the dark, and store it in a dark container preferably under N2. It has at 220.5nm (log 3.79) and 280nm (log 3.42) in 0.001N max HCl. [Yamada et al. Chem Pharm Bull Jpn 10 693 1962, Bretschneider et al. Helv Chim Acta 56 2857 1973, NMR: Jardetzky & Jardetzky J Biol Chem 233 383 1958, Beilstein 4 IV 2492, 2493.]Levodopa 준비 용품 및 원자재
원자재
Cation exchange resin,strong acidic styrene
L-(-)-티로신
세피아
1,3,5-트라이메틸벤젠
1,2-디올레오일-SN-글리세로-3-인산나트륨염
아세트산(빙초산)
준비 용품
(S)-(-)-6,7-DIMETHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID HYDROCHLORIDE
N-(tert-buloxycarbonyl)-3,4-dihydroxy-L-phenylalanine
(S)-메틸2-((tert-부톡시카르보닐)아미노)-3-(3,4-디히드록시페닐)프로파노에이트
5,6-디히드록시-1H-인돌-2-카르복실산
테트라히드로파파베롤린
FMOC-DOPA(아세토나이드)-OH
L-3,4-디히드록시페닐알라닌메틸에스테르염산염
(2S)-5,6-dihydroxy-2,3-dihydro-1H-indole-2-carboxylic acid
Levodopa 공급 업체
글로벌( 768)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
career henan chemical co | +86-0371-86658258 +8613203830695 |
sales@coreychem.com | China | 29886 | 58 |
APOLLO HEALTHCARE RESOURCES | +6596580999 |
sales@apollo-healthcare.com.sg | Singapore | 399 | 58 |
Chengdu ChenLv Herb Co.,Ltd | +86-13608205856; +undefined13608205856 |
maryextract@126.com | China | 127 | 58 |
Sinoway Industrial co., ltd. | 0592-5800732; +8613806035118 |
xie@china-sinoway.com | China | 988 | 58 |
Hong Kong Excellence Biotechnology Co., Ltd. | |
ada@sh-teruiop.com | China | 875 | 58 |
Changzhou Rokechem Technology Co., Ltd. | 18758118018 |
sales001@rokechem.com | China | 255 | 58 |
HangZhou RunYan Pharma Technology Co.,LTD. | +8618882027439 |
sales2@runyanpharma.com | China | 302 | 58 |
Henan Bao Enluo International TradeCo.,LTD | +86-17331933971 +86-17331933971 |
deasea125996@gmail.com | China | 2472 | 58 |
Xiamen Wonderful Bio Technology Co., Ltd. | +8613043004613 |
Sara@xmwonderfulbio.com | China | 283 | 58 |
Hebei Kingfiner Technology Development Co.Ltd | +86-15532196582 +86-15373005021 |
lisa@kingfinertech.com | China | 2990 | 58 |
Levodopa 관련 검색:
구아니딘 아세트산 L-카르니틴 L-알라닌 레바미졸 3,4-다이하이드록시-알파-메틸페닐알라닌 L-(-)-티로신
H-ARG-ARG-LEU-ILE-GLU-ASP-ASN-GLU-TYR-THR-ALA-ARG-GLY-OH
Boc-D-Tyr-OH
TYROSINASE
Phenibut
4-Ethoxy-N,N,N-trimethyl-4-oxo-1-butanaminium chloride
L(-)-Carvone
L(-)-Carnitine hydrochloride
L-Carnitine fumarate
Levosulpiride
L-Carnitine-L-tartrate
Levofloxacin carboxylic acid
(R)-(-)-Epichlorohydrin